Published Medical Literature

Novel BRCA2 Mutation Strengthens Evidence for Germline Genetic Testing

Black Breast Cancer Survivors and the Psychosocial Challenges They Face

Palbociclib’s Benefits in Metastatic Breast Cancer Assessed in Real-World Analysis

Does a Certain Protein Complex Contribute to Endocrine Resistance in Breast Cancer?

Medicaid Expansion in Southern U.S. States and Breast Cancer

Preventing Hyperglycemia in Patients Being Treated for Advanced Breast Cancer

Use of a Plasmid DNA Vaccine in Treatment of Advanced, HER2-Positive Breast Cancer

Can Patients With Invasive Breast Cancer Who Respond to Neoadjuvant Chemotherapy Avoid Surgery?

New Metabolic Biomarkers May Improve the Ability to Predict Breast Cancer Recurrence

Expanding the Use of PARP Inhibitors in Breast Cancer: Focus on Talazoparib and PALB2

Phase III Trial of Sacituzumab Govitecan in HR-Positive, HER2-Negative Advanced Breast Cancer

Neoadjuvant Chemotherapy and the Immune Landscape in Early-Stage Breast Cancer

Early-Stage Breast Cancer: Use of Contraception in Premenopausal Patients

Targeting ABL-Dependent Brain Metastatic Targets in HER2-Positive Breast Cancer

Pembrolizumab Plus Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355

Chronic Inflammation and Cognitive Problems: Potential Link in Older Breast Cancer Survivors

Treating Non–Low-Risk Ductal Carcinoma In Situ With Tumor Bed Boost After Whole-Breast Irradiation

Could Digital Breast Tomosynthesis Provide Better Screening Than Digital Mammography?

Batwing Mastopexy and Aesthetic Outcomes for Patients With Breast Cancer

Study Finds Breast Tissue Features on MRI May Be Linked to Risk for Second Breast Cancer

IMpassion050 Trial: Combining Standard of Care With Immunotherapy for High-Risk Breast Cancer

Performance of Diagnostic Mammography Seems to Vary Across Racial/Ethnic Groups

Does Receipt of Genetic Counseling Make Uptake of Genetic Testing in Breast Cancer More Likely?

Are Vaginal Estrogen and Menopausal Hormonal Therapies Linked to an Increased Risk of Breast Cancer Recurrence?

GeparX Trial: Adding Denosumab to Nab-Paclitaxel Regimens in Breast Cancer

Is the von Willebrand Factor Linked to Metastasis of Breast Cancer?

COVID-19 and Breast Cancer: Impact on Surgical Treatment and Breast Reconstruction

Trends in Racial Disparity in Breast Cancer Mortality in the United States

Is Etirinotecan Pegol Superior to Chemotherapy in Treating Brain Metastases From Breast Cancer?

A Possible Biological Mechanism Connecting Type 2 Diabetes and Breast Cancer?

Predicting Breast Cancer Using Digital Breast Tomosynthesis Screening: A Risk Model

Ratiometric Combination Nanoprodrug Strategy Under Study in Triple-Negative Breast Cancer

Is There a Link Between Vitamin D Levels and Breast Cancer in Multiethnic/Racial Groups?

Sodium Levels in Breast Cancer: Predicting Tumor Aggressiveness and Therapeutic Response

Can Cytosine and Guanine Nucleotide Pairs Influence Epigenetic Aging of Breast Tissue?

Surveillance Mammography in Older Breast Cancer Survivors: Patient Survey Findings

Compression Sleeves Used Prophylactically May Reduce or Delay Breast Cancer–Related Lymphedema

Pyrotinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: Phase II PERMEATE Trial

Use of Adjuvant Trastuzumab After Surgery to Reduce Recurrence of Breast Cancer

Is the Acne Medication Spironolactone Linked to Increased Risk for Breast Cancer?

KEYNOTE-522: Event-Free Survival With Pembrolizumab in Triple-Negative Breast Cancer

Gene Amplification: Novel Strategy Against Drug Resistance in HER2-Positive Breast Cancer

Which Genetically Predisposed Older Women Should Undergo Breast Cancer Screening?

Dietary Acid Load and Associated Mortality After Breast Cancer on Long Island, New York

Potential Link Between Insomnia and Its Treatment and Risk of Breast Cancer in Women?

Comparing Palbociclib-Based Therapies in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

CDK4/6 Inhibitor Plus Fulvestrant and Overall Survival in Breast Cancer: FDA Pooled Analysis

Can Skin Electrical Resistance Be Used as a Screening Tool for Breast Cancer?

HER2-Targeted Therapies With SRS for Breast Cancer Metastatic to the Brain

5-Year Results With Intraoperative Radiotherapy Among Black Women With Breast Cancer

Neoadjuvant Dual Anti-HER2 Therapy for HER2-Positive Breast Cancer: Long-Term Outcomes After Surgery

Chromosomal Instability: Biomarker for Predicting Response to Paclitaxel in Breast Cancer?

Early-Phase Study of Cabozantinib Plus Atezolizumab in Advanced Triple-Negative Breast Cancer

Intratumoral Immune Therapy for Recurrent Breast Cancer

Does Internal Mammary Node Irradiation Improve Outcomes in Node-Positive Breast Cancer?

Persistent Chemotherapy-Induced Alopecia: Is It Partially Reversible in Breast Cancer Survivors?

One Drug or Two for Metastatic Breast Cancer? The Decision May Depend on Serum Enzymes

Pyrotinib Under Study in Metastatic HER2-Positive Breast Cancer With Brain Metastasis

Dosing Intervals of Vinorelbine Under Study in HER2-Negative Breast Cancer

OlympiA: Adjuvant Olaparib for HER2-Negative Early Breast Cancer With BRCA1 or BRCA2 Germline Mutation

Real-World View From Germany: Bevacizumab-Containing Therapy for Locally or Metastatic Breast Cancer

Active Living After Cancer: Exercise Program for Underserved Breast Cancer Survivors

Fulvestrant or Exemestane After Adjuvant Therapy for Advanced Breast Cancer

Investigating Racial Disparities in Survival Outcomes Among Women Treated for Breast Cancer in Atlanta

HER2-Low–Positive Tumors: A New Subgroup of Breast Cancers Identified by IHC?

Reducing Levels of CA 15-3 With Metformin in Patients With Early-Stage Breast Cancer

COVID-19 and Breast Cancer Screening: View From a San Francisco Safety-Net Hospital

Can Behavioral Therapy Relieve Headaches for Breast Cancer Survivors?

ERBB2-Positive Breast Cancer: How Does T-DM1 Measure Up Against Standard Neoadjuvant Treatment?

Stem Cell–Derived Dendritic Cells With Radiotherapy Under Study in Preclinical Breast Cancer Models

COVID-19 and Breast Cancer Screening: Who Is at Risk for Delayed Mammography?

Adjuvant Treatment of Early-Stage Breast Cancer: T-DM1 Versus Paclitaxel Plus Trastuzumab

Early Breast Cancer: 5 Years Versus 3 Years of Adjuvant Bisphosphonate Treatment

Chemotherapy De-escalation Strategy Under Study in Early HER2-Positive Breast Cancer

Preclinical Study of Lasofoxifene in Endocrine Therapy–Resistant Breast Cancer

Prevalence of Germline Pathogenic Variants in Black Women Versus Non-Hispanic White Women

COVID-19 and Breast Cancer Screening in Washington State: Did Socioeconomics Play a Role?

Can Tumor Marker Help to Predict Response to HER2 Inhibition in Breast Cancer?

Early Estrogen Receptor–Positive Breast Cancer: Are Older Women Being Overtreated?

Racial Disparities in Mortality Risk for Women With Triple-Negative Breast Cancer

Aspirin, Clopidogrel, and Risk of Breast Cancer in Postmenopausal Women

PRADA Trial: Is Routine Cardioprotection Required With Early Breast Cancer Therapy?

Are All Triple-Negative Breast Cancers Created Equal?

ASCENT Trial: Antibody-Drug Conjugate Improves Outcomes in Triple-Negative Breast Cancer

Ribociclib-Based Therapy for Advanced Breast Cancer Under Study

Can Salpingo-oophorectomy Reduce the Likelihood of Breast Cancer in High-Risk Women?

Can PET-Based Estradiol Challenge Test Monitor Response to Endocrine Therapy?

Breast Tumor Microenvironment: Differences in Black Women?

Consecutive Mammography Screening and Risk of Breast Cancer Mortality

Common Pathogenic Variants in Breast and Ovarian Cancers: From a Caribbean Perspective

KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer

Lifetime Smoking and the Risk for Breast Cancer

Revelations About Genes Linked, and Not Linked, to Breast Cancer: Population-Based Study

Are Breast Cancer Survivors at Increased Risk for Cardiovascular Diseases?

Does Use of Aspirin Improve Outcomes in Older Patients With Breast Cancer?

Are National Screening Targets Being Achieved for Breast Cancer?

Can Older Women With Triple-Negative Breast Cancer Benefit From Adjuvant Chemotherapy?

Can Low-Dose Capecitabine Maintenance Improve Outcomes in Triple-Negative Breast Cancer?

PEARL Trial in Metastatic Breast Cancer: Palbociclib Plus Endocrine Therapy Versus Capecitabine

Using Ki67 Index to Select Appropriate Adjuvant Therapy for Early Breast Cancer

Strategy for Reducing Fatigue in Breast Cancer Survivors: Combined Exercise and Mindfulness Training

Does Fertility Preservation Increase Childbirth Rates in Women With Breast Cancer?

Access to the Affordable Care Act and Breast Cancer Diagnosis: Pennsylvania Perspective

Accelerated Partial-Breast Versus Whole-Breast Irradiation in Early Breast Cancer

Adding ErbB Inhibitor to Standard Chemotherapy for HER2-Positive Breast Cancer

Effect of Chemotherapy on Quality of Life of Older Women With Breast Cancer

Novel DNA Repair–Related Gene Prognostic Model for Patients With Breast Cancer

Use of Abbreviated Breast MRI to Screen for Breast Cancer in Women With Dense Breasts

Pembrolizumab Plus T-Cell Inducer Under Study in Triple-Negative Breast Cancer

Update on Systemic Therapies for Breast Cancer: ‘Pragmatic Decision-Making’ Still Needed

Impact of Early Mammographic Screening on Breast Cancer Mortality: UK Age Trial

Ribociclib Plus Fulvestrant With or Without PI3K Inhibitor in Advanced Breast Cancer

Repurposing Aspirin for Chemoresistant Breast Cancer Cells

Trastuzumab Monotherapy for Older Patients With HER2-Positive Breast Cancer

Adverse Opioid-Related Events in Older Breast Cancer Survivors

Chemotherapy-Induced Neutropenia: Alternative Treatment Under Study in Early-Stage Breast Cancer

Researchers Identify Three New Genetic Variants Linked to Male Breast Cancer

Considerations in the Locoregional Treatment of Patients With Early-Stage Breast Cancer

Early-Stage Breast Cancer: Treatment Choices for Women With Young Children

Efficacy of Chemotherapy Plus Checkpoint Inhibition in Metastatic Breast Cancer Under Study

Triple-Negative Breast Cancer: Mixed 19-Peptide Vaccine Monotherapy

Search for Optimal Dose of Nab-paclitaxel for Older Patients With Advanced Breast Cancer

Early Breast Cancer or DCIS: Hypofractionated Versus Standard-Fractionated Radiotherapy

Does Timing of Neoadjuvant Chemotherapy Affect Outcomes in Early-Stage Breast Cancer?

Opioid Use After Surgical Resection of Breast Cancer

Are Circadian Disruption and Breast Carcinogenesis Related?

CHK1 Inhibitor in BRCA Wild-Type Triple-Negative Breast Cancer

Music May Help Women in Chemotherapy for Breast Cancer

CLCA2 Expression: Prognostic Biomarker for Triple-Negative Breast Cancer in Black Women?

Lessons From NALA: Biomarkers of Treatment Response in Metastatic Breast Cancer

Does Exercise Improve Outcomes in Patients Treated for High-Risk Breast Cancer?

Patient-Reported Barriers to Discussing Sexual Concerns With Health-Care Providers

Quality of Life During Pembrolizumab Treatment for Metastatic Triple-Negative Breast Cancer

Subcutaneous Versus Intravenous Pertuzumab/Trastuzumab in Early Breast Cancer: Patient Perspective

Phase III Trial of Triplet Regimen for HER2-Positive Metastatic Breast Cancer

Combination of Abemaciclib, Pembrolizumab, and Anastrozole in Metastatic Breast Cancer

Ipatasertib Plus Paclitaxel in Triple-Negative Breast Cancer: Final Results of LOTUS Trial

Link Between Polypharmacy and Inpatient Hospitalization in Older Patients With Breast Cancer?

Identifying Cancer in Dense Breasts: Abbreviated MRI Versus 3D Mammography

Does Neoadjuvant Chemotherapy Streamline Breast Cancer Treatment?

Updated ASCO Guidelines on Male Breast Cancer: Different Approaches for Men and Women?

Assessment of Genetic Mutations in Postmenopausal Women With Breast Cancer

Cognitive Impairment in Women With Breast Cancer: Comparison of Adjuvant Therapies

Ductal Carcinoma in Situ: Link Between Estradiol/Testosterone Levels and Increased Risk?

Relationship Between Thyroid Dysfunction and Risk of Breast and Thyroid Cancers

CA 15-3 and Vitamin D: Prognostic Indicators in Patients Treated for Breast Cancer?

Breast Cancer and COVID-19: Alternative Radiation Therapies

Shortened Course of Radiotherapy for Breast Cancer: 5-Year Results From FAST-Forward Trial

Psychosocial Status and Geriatric Abnormalities in Metastatic Breast Cancer

PALB2-Associated Risks of Breast and Other Cancers

Got Milk? Study Finds Potential Link Between Dairy Intake and Breast Cancer

Germline Genetic Testing and Treatment Variation in Women With Breast Cancer

Preventive Tamoxifen Therapy: Are Women Aware of the Risks Along With the Benefits?

Does Extended Adjuvant Capecitabine Improve Survival in Triple-Negative Breast Cancer?

Should There Be an Upper Age Limit for Annual Screening Mammography?

Pathologic Complete Response With Pembrolizumab for Triple-Negative Breast Cancer

Heat Shock Protein 47 and Breast Cancer Metastasis

Risk of Ischemic Heart Disease After Radiotherapy for Breast Cancer

21-Gene Assay Recurrence Score in Predicting Locoregional Recurrence of Breast Cancer

Investigators Map Genetic Variants Linked to Breast Cancer

Second-Line Gemcitabine With Dual Antibody Therapy for ERBB2-Positive Metastatic Breast Cancer

AKT Inhibitor Plus Paclitaxel in Metastatic Triple-Negative Breast Cancer

Microflora and Breast Cancer: Are Some Bacteria Protective and Others Not?

Neoadjuvant Therapy and Eligibility for Breast Conservation in Triple-Negative Disease

Breast Cancer Screening: Personalizing Starting Age Based on Reproductive Factors

Ribociclib Plus Fulvestrant for Advanced Breast Cancer: Update From MONALEESA-3

Does Use of Dietary Supplements During Chemotherapy for Breast Cancer Improve Survival?

Does Treatment Delay Differentially Impact Overall Survival Across Breast Cancer Phenotypes?

Total Cumulative Dose of Chemotherapy and Breast Cancer Survival Rates

Metastatic Sites and Survival Outcomes Among Patients With Advanced Breast Cancer

Use of Supplemental MRI Screening in Women With Extremely Dense Breast Tissue

Proton Beam Radiotherapy for Nodal Irradiation in Patients With Breast Cancer

Update on Prognosis Patterns in Men With Breast Cancer

Breast Cancer Mortality Risk in Women With a History of Thyroid Cancer

GeparSepto Trial: Long-Term Results With Nab-paclitaxel in Early Breast Cancer

Stromal Tumor-Infiltrating Lymphocytes: Prognostic Indicator in Triple-Negative Breast Cancer?

Adjuvant Trastuzumab and Cardiac Toxicities in Patients With Breast Cancer

KATE2 Trial: Updated Overall Survival With Immunotherapy Combination in Advanced Breast Cancer

Machine Learning May Improve Accuracy of Breast Cancer Diagnoses

Update on CDK4/6 and Aromatase Inhibitors in Older Women With Breast Cancer

Is Sex a Contributing Factor to Mortality Disparity in Breast Cancer?

Is Breast Cancer Screening Effective in High-Risk Men?

Insurance and Mortality in Breast and Other Cancers

Final Results of MARIANNE Trial of T-DM1 in HER2-Positive Advanced Breast Cancer

Menopausal Hormone Replacement Therapy and Increased Risk of Breast Cancer

Niraparib Plus Pembrolizumab in Advanced Triple-Negative Breast Cancer

Learning More About Breast Cancer in Adolescents and Young Adults

Breast Cancer Screening in Women With Familial Risk: MRI or Mammography?

Timeliness of Chemotherapy Initiation After Breast Cancer Diagnosis and Survival

TAILORx Trial: Predicting Benefit From Chemotherapy in Early Breast Cancer

Adjuvant Trastuzumab for HER2-Positive Breast Cancer: Results of Two Phase III Trials

HannaH Trial: Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer

Role of Lymphoscintigraphy in Sentinel Lymph Node Biopsy for Early Breast Cancer

Pain and Depression in Patients Treated for Breast Cancer

Parity-Associated Gene Expression and Breast Cancer in Premenopausal Women

How an Intervention Trial Addressed Racial Disparities in Treatment of Early-Stage Cancers

Targeting Triple-Negative Breast Cancer With Combination of PARP Inhibitors

Overall Survival With CDK4/6 Inhibitor in Hormone Receptor–Positive Breast Cancer

Niraparib Plus Pembrolizumab in Triple-Negative Breast Cancer: TOPACIO/KEYNOTE-162 Trial

Lifetime Incidence of Brain Metastasis in Elderly Survivors of Breast Cancer

Long-Term Outcomes With Adjuvant Paclitaxel and Trastuzumab in HER2-Positive Breast Cancer

Eribulin Versus Vinorelbine in Locally Recurrent or Metastatic Breast Cancer

Does Primary Care Appointment Time Affect Breast Cancer Screening Rates?

Chronic Opioid Use in Breast Cancer Survivors

Potential Prognostic Marker Identified for Triple Negative Breast Cancer

Genetic Testing in Patients With Breast and Ovarian Cancers

Preoperative Breast MRI and Surgical Outcomes in Local Ductal Carcinoma in Situ

Linking Pregnancy and the Genomic Landscape of Subsequent Breast Cancer

Breast Cancer Risk in Women With BRCA Mutations: Role of Number of Pregnancies

Addition of First-Line Fulvestrant to Anastrozole in Metastatic Breast Cancer

Long-Term Follow-up of Adjuvant Tamoxifen in Women With Breast Cancer

KAMILLA Trial: T-DM1 Safety in HER2-Positive Breast Cancer

Complications After Immediate Implant-Based Breast Cancer Reconstruction

Can Celecoxib Be Used to Treat HER2-Negative Breast Cancer?

Ovarian Function Suppression in Women With Breast Cancer: Degarelix Versus Triptorelin

Extended Letrozole Therapy After Aromatase Inhibitor–Based Therapy in Breast Cancer

Survival Outcomes With Palbociclib and Fulvestrant in Breast Cancer

Addition of Palbociclib to Letrozole in Estrogen Receptor–Positive Breast Cancer

Is There a Link Between Childbirth and Breast Cancer Risk?

Anthracycline Use in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Axillary Radiotherapy as an Alternative to Axillary Lymph Node Dissection for Early Breast Cancer

Cosmetic Outcomes With Irradiation in Stages 0 to II Breast Cancer

Novel Statistical Approach Calculates Risk of Breast Cancer Recurrence in American Women

Extending Aromatase Inhibitor Therapy in Breast Cancer

Continued Benefit of Adding Goserelin to Chemotherapy in Women With Breast Cancer

Combination of Paclitaxel, Sorafenib, and Radiation in Advanced Breast Cancer

Lucitanib for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

PALB2 Mutation in Hereditary Breast and Ovarian Cancer

How Accurate Are NCDB Comorbidity Assessments in Breast Cancer and Other Resected Tumors?

Racial Differences in Adherence to Endocrine Therapy for Breast Cancer

Update on Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors

Atezolizumab in Metastatic Triple-Negative Breast Cancer: Long-Term Outcomes

Population-Level Genomic Screening for Hereditary Breast Cancer

Alliance Study: Comparing Neoadjuvant Therapy Approaches in HER2-Positive Breast Cancer

Are Fertility-Related Hormone and Breast Cancer Development Linked?

Novel Tool to Predict Risk of Late Distant Recurrence in Patients With Breast Cancer

Update on Trends in Breast Cancer Survival Among Young Women

Impact of Screening on Breast Cancer Mortality Assessed in Danish Study

Can Circulating Tumor Cells Predict Late Recurrence in Breast Cancer?

Long-Term Safety Profile of Palbociclib With Endocrine Therapy

ASCO Clinical Practice Guidelines Updates in Advanced HER2-Positive Breast Cancer

Neoadjuvant Chemotherapy Plus Panitumumab in Inflammatory Breast Cancer

ASCO Guideline Update: Adjuvant Chemotherapy and Targeted Therapy for Breast Cancer

Fear and Worry Over Breast Cancer Among Women Facing Surgical Decisions

Comparing Trastuzumab Biosimilar and Reference Trastuzumab in HER2-Positive Breast Cancer

Update to ASCO/CAP Guidelines on HER2 Testing in Breast Cancer

Association of Prognosis in Early Breast Cancer With Somatic Driver Alterations

Safety of Pregnancy After Estrogen Receptor–Positive Breast Cancer

Clinical Relevance of Multigene Sequencing in Patients With Breast Cancer

Are Long-Term Survivors of Triple-Negative Breast Cancer Being Referred for Genetic Counseling?

Link Between CTC Status and Radiotherapy Benefit in Early-Stage Breast Cancer

Screening for Intracranial Disease in Patients With Metastatic Breast Cancer

Cardiovascular Risks Associated With Breast Cancer and Its Treatments

Are Patients Diagnosed With Breast Cancer Receiving Clinically Indicated Genetic Counseling?

Disparities in Genetic Testing for Hereditary Breast Cancer in the United States

Is Hormone Therapy a Risk Factor for Diabetes in Breast Cancer Survivors?

Novel Second-Line Treatment of Aromatase Inhibitor–Resistant Breast Cancer

Genetic Biomarker as Potential Predictor of Platinum Sensitivity in Triple-Negative Breast Cancer

Addition of Veliparib to Standard Neoadjuvant Therapy in Triple-Negative Breast Cancer

Predicting Risk of Breast Cancer: Automated Versus Clinical Assessment of Breast Density

Postmastectomy Radiation Therapy for Locoregional Control of Breast Cancer

CALOR Trial: Adjuvant Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer

Use of Metronomic Chemotherapy in Older Patients With Metastatic Breast Cancer

Bone Turnover Markers in Metastatic Breast Cancer

Combination Therapy Under Study in Treatment-Resistant Breast Cancer

First-Degree Family History and Breast Cancer Risk in Women Older Than Age 65

Androgen Receptor–Targeted Treatment in Triple-Negative Breast Cancer

Distant and Locoregional Recurrence in Stage II or III Breast Cancer

Updated Results on Neratinib in HER2-Positive Breast Cancer

Correlation Between Breast Cancer Mortality and Advances in Screening and Treatment

Neoadjuvant Versus Adjuvant Chemotherapy in Early Breast Cancer

Dual HER2 Blockade in Metastatic Breast Cancer

Pertuzumab-Containing Neoadjuvant Regimens in HER2-Positive Breast Cancer

Dual HER2-Targeting Treatments for Postmenopausal Women With Metastatic Breast Cancer

Hormonal Birth Control and Invasive Breast Cancer Risk

Safety Profile of Buparlisib Plus Fulvestrant in Advanced Breast Cancer

Survival Benefit of Intense Dose-Dense Chemotherapy in High-Risk Breast Cancer

Use of Duloxetine for Arthralgias Associated With Breast Cancer Treatment

Letrozole Schedules Compared in Postmenopausal Women With Breast Cancer

Textured Breast Implants and Rare Anaplastic Lymphoma

Type 2 Diabetes and Breast Cancer Subtype in African American Women

Cardiac Effects of Trastuzumab Therapy in Patients With HER2-Positive Breast Cancer

Bacterial Imbalances and Breast Cancer

Initial Therapy With Abemaciclib for Advanced Breast Cancer

Effect of 5 Years’ Endocrine Therapy on Breast Cancer Recurrence

cT1–2N0 Breast Cancer: Less- and More-Invasive Treatment Results

Mortality in Elderly, Mentally Ill Breast Cancer Patients

Physicians’ Views on Radiotherapy for Older Women With Early-Stage Breast Cancer

Neoadjuvant Combination Therapy for HER2-Positive Primary Breast Cancer

HER2-Targeted Therapy and Breast Reconstruction

Soy Foods and Breast Cancer Survival

Surgeon Impact on the Decision to Have Contralateral Prophylactic Mastectomy

Investigational AKT Inhibitor in Triple-Negative Breast Cancer

Neoadjuvant Ado-trastuzumab Emtansine vs. Trastuzumab in Early Breast Cancer

Tamoxifen Metabolite Z-Endoxifen in Metastatic Breast Cancer

Current Treatment Approaches for Triple-Negative Breast Cancer

Response to Immunotherapy in Patients With ‘Claudin-Low’ Breast Tumors

Comparing Trastuzumab-Based Regimens in Older Women With Early-Stage Breast Cancer

Surveillance Mammography for Older Survivors of Breast Cancer

Wound Complications After Breast Reconstruction Procedures

Potential Toxicities Associated With CDK4/6 Inhibitors in Breast Cancer

Using Molecular Signature to Identify Indolent Breast Tumors

Oral Vinorelbine in Patients With Endocrine-Pretreated Breast Cancer

Changes in Histology and Breast Cancer Risk

MONARCH 2: Abemaciclib/Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer

Adding Pertuzumab to Trastuzumab and Chemotherapy in HER2-Positive Breast Cancer

Final Survival Data From TH3RESA Trial in Breast Cancer

Final Overall Survival Data From EMILIA Trial

Biologic Differences in Invasive Breast Cancers Among Black and White Patients

OlympiAD Trial: Olaparib in HER2-Negative Metastatic Breast Cancer

Additional Surgery After Initial Lumpectomy

Patient Satisfaction With Breast Reconstruction

More Women Living With Metastatic Breast Cancer

Combining Monoclonal Antibodies in HER2-Positive Breast Cancer

ABC Breast Cancer Trials of Adjuvant Taxane With or Without Anthracycline in HER2-Negative Disease

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Optimizing Adherence to Oral Chemotherapy

Steadily Increasing Breast Cancer Rates in Asian Americans

Study Finds Discrepant Decision-Making for Use of 21-Gene Assay in Women With Early-Stage Breast Cancer

Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors

Contralateral Prophylactic Mastectomy Decisions in Patients With Early-Stage Breast Cancer

Identifying Educational Needs of the Multidisciplinary Cancer Team in the Treatment of Metastatic Breast Cancer

A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer

Improved Survival With Higher TIL Values in Advanced HER2-Positive Breast Cancer

A Review of Treatment for Breast Cancer–Related Lymphedema: Paradigms for Clinical Practice

Stereotactic Radiosurgery for Treatment of Brain Metastases

Clinical Trial Data Model: What Can It Offer Health-Care Professionals Who Treat Breast Cancer?